Showing results (301-310 of 742) with videos related to

Sort By:
Pageof 75
Blood Advances|March 3, 2019
Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myelomaNidhi Tandon, Surbhi Sidana, S Vincent Rajkumar, et al.
Leukemia|February 10, 2019
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosisYi L Hwa, Morie A Gertz, Shaji K Kumar, et al.
British Journal of Haematology|August 3, 2026
High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patientsY Lisa Hwa, Dragan Jevremovic, Karen Pak, et al.
Cancer|April 23, 2008
Malignant primary cardiac tumors: review of a single institution experienceLijo Simpson, Shaji K Kumar, Scott H Okuno, et al.
Clinical Transplantation|July 22, 2014
Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myelomaChintan Pandya, Shahrukh Hashmi, Nandita Khera, et al.
Blood Cancer Journal|February 10, 2021
Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)Li Pang, S Vincent Rajkumar, Prashant Kapoor, et al.
Blood|July 19, 2011
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myelomaRishi K Wadhera, Robert A Kyle, Dirk R Larson, et al.
Blood|May 16, 2002
Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemiaRuben A Mesa, Curtis A Hanson, Chin-Yang Li, et al.
Blood|July 10, 2015
Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myelomaA Keith Stewart, Susanna Jacobus, Rafael Fonseca, et al.
The New England Journal of Medicine|January 18, 2018
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined SignificanceRobert A Kyle, Dirk R Larson, Terry M Therneau, et al.
Pageof 75